Proprietary molecular dynamics models form a core part of our digital formulation screening approach.
Our scientists utilise these proprietary models to cut down the time needed for asset formulation feasibility studies.
We also have an opportunity to screen for new assets using this technology further strengthening our pipeline.
Our carrier particles are plug-and-play in nature allowing for rapid drug loading into carrier pores, thus prototype formulations can be made within days versus months/years with traditional formulation approaches.
Our platforms ensure both stability and scalability facilitating swift translation of formulations into clinical assets.
Our carrier technologies utilise excipients listed in the FDA inactive ingredients database thus eliminating any potential safety or toxicity issues.
The manufacturing processes are scalable to pilot and commercial scales and we work with specialist CDMOs to manufacture our products under cGMP.
Sustainability is in the heart of our mission to expedite the development of therapeutics with speed and resource-efficiency. Utilising our unique digital capabilities, we can limit solvent usage, product waste and ensure formulations are developed efficiently.
